Publication:


abstract

asthma is characterized by variable and reversible airflow limitation and bronchial hyperresponsiveness due to chronic airway inflammation. Asthma Treatment is based on the patients' asthma control status. Central to treatment recommendations is anti-inflammatory therapy with inhaled corticosteroids plus a rapid-acting β(2)-agonist as required. If this is not sufficient to achieve at least partial asthma control, the dose of the inhaled corticosteroid should be increased and a long-acting β(2)-agonist should be added. Other controllers, such as leukotriene antagonists or slow-release theophylline are alternative or additive options. Systemic treatment with corticosteroids and/or the monoclonal anti-IgE antibody omalizumab are reserved for patients with severe asthma. strategies aimed at preventing airway irritation, reducing exposure to exogenous allergens and inhaled irritants as well as asthma education are other key elements of asthma management.

Related Articles
Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Pediatrics. 2001
Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P. Pediatrics. 2001 Aug; 108(2):E36.
Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).
Treat Respir Med. 2006
Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).
D'Amato G, Bucchioni E, Oldani V, Canonica W. Treat Respir Med. 2006; 5(6):393-8.
Asthma challenges: The place of inhaled long-acting beta-agonists.
Cochrane Database Syst Rev. 2010
Asthma challenges: The place of inhaled long-acting beta-agonists.
Tovey D. Cochrane Database Syst Rev. 2010 Apr 14; 8:ED000002. Epub 2010 Apr 14.
Review Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?
Drugs. 2001
Review Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?
Holimon TD, Chafin CC, Self TH. Drugs. 2001; 61(3):391-418.
Review A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
Recent Pat Inflamm Allergy Dru...
Review A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G, Piccolo A, Salzillo A, Noschese P, D'Amato M, Liccardi G. Recent Pat Inflamm Allergy Drug Discov. 2007 Nov; 1(3):225-31.